Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose metronomic temozolomide + sorafenib in recurrent glioblastoma multiforme
2008-001763-11Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Oct 2008
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and sorafenib in glioblastoma (GBM), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: 6-month progression-free survival. Started Oct 2008; status: active.
02
Drugs
temozolomidesorafenib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-001763-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001763-11.